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analogues [13] . Furthermore, the in vivo evaluation of DIG-MSK antitumor activity through hollow fiber assays using 12 tumor cell lines and cancer xenograft models indicates that this compound could be a promising antitumor drug against colon, breast, ovarian, melanoma, nonsmall-cell lung and central nervous system cancers [13] .
We have reported that several mithramycin analogues show differences in both the magnitude of their binding to DNA and the exact composition of their C/G-rich preferred binding sites. These differences might depend on the composition of their respective side chains attached at C-3 [15, 16] .
Here, we compare the effects of MTA and the structurally related analogues DIG-MSK and MSK on DNA binding and cellular and nuclear accumulation in A2780, IGROV1 and OVCAR3 human ovarian cancer cell lines. MSK has profound effects on the growth and survival of those ovarian cancer cells [17] , including A2780 xenografts [18] , as well as on other cancer cells [19] .
Several transcription factors that recognize C/G-rich tracts in promoters have been identified as potential targets for MSK and DIG-MSK, thus providing further evidence on the "transcription factor-based" action of mithramycin analogues [14, 17, 20] . The levels of Sp1 transcription factor are frequently altered in numerous human cancers [21] , and the expression of Sp1 is enhanced in ovarian cancer [18] . Because MSK is a potent inhibitor of Sp1-dependent transcription both in vitro and in tumor xenografts [18] , we explore the effects of structurally related DIG-MSK on Sp1-mediated transcription. We aimed at gaining further insights into the DIG-MSK mechanism of action by direct comparison with the effects of the parental MTA, a compound that is routinely used in different experimental systems to assess the role of the Sp1 transcription factor in gene expression, and the function of this transcription factor in cancer (see, [22] [23] [24] , and references therein) as well as to abrogate Sp1 expression in vivo [9] . Furthermore, we examine the effect of these mithramycins on Sp3, another member of the Spfamily of transcription factors which also binds with similar affinity to C/G-rich sequences [25] .
To this end, the effect of MTA and DIG-MSK on ULBP1 promoter activity and gene expression was also analyzed. ULBP1 is a ligand of the NKG2D receptor expressed by NK and T cells, which is involved in the immune surveillance of cancer [26, 27] , and it is a predictor of poor prognosis in ovarian cancer [28] . The effects of mithramycin analogues on the ULBP1 promoter activity are of interest because this is one of the few genes in which Sp3, but not Sp1, is a key gene regulator, increasing more than 500-fold the ULBP1 promoter activity [26, 27] . We observed that the effect of the novel DIG-MSK on transcription depends on the cell line examined and, in general, it is equivalent, or even stronger, than the parental MTA.
Materials and methods

Mithramycins
Mithramycin A (MTA), mithramycin SK (MSK) and demycarosyl-3D-β-D-digitoxosylmithramycin SK (DIG-MSK; EC-8042) were isolated and purified from the producing organisms as described previously [4, 13] , and their purity (≥ 97%) was checked by HPLC. Stock solutions of the different compounds were prepared at either 10 mM in DMSO or 500 mM in 50 mM NaCl, 20 mM Hepes (pH 7.5), kept at -20°C, and diluted to the desired concentration before the experiments, using the same buffer or tissue culture medium. When required for the different experiments, MgCl 2 was added to the same buffer at various concentrations in the 1 to 3 mM range.
Fluorescence spectroscopy
Fluorescence spectroscopy experiments were carried out in a Cary Eclipse fluorescence spectrophotometer (Varian Inc.) using 1-cm pathlength, as described previously [16] with minor modifications. In brief, DNA binding was measured by fluorescence titration (λ ex : 410 nm, λ em : 548 nm) of 22 µM solutions of DIG-MSK dissolved in 50 mM NaCl, 20 mM Hepes (pH 7.5) containing either 1, 1.5 or 3 mM MgCl 2 and incubated for 1 h at 25 ºC or 37 ºC to ensure the Mg 2+ -mediated dimerization of the compounds. Small aliquots of sonicated calf thymus DNA (Sigma) in the same buffer were added to the drug solutions and the fluorescence spectra obtained after 3 min equilibrium at both 25 ºC and 37 ºC.
Thermal denaturation studies
Ultraviolet DNA melting curves were determined using a Jasco V-650 spectrophotometer equipped with an ETC-505T (Jasco) temperature controller. Samples contained 20 µM (in bp) sonicated calf thymus DNA (Sigma) and either MTA, MSK or DIG-MSK to obtain drug/DNA molar ratios of 0.25 (enough to saturate the potential drug-binding sites [16] ) in 50 mM NaCl, 20
mM Hepes (pH 7.5) containing 1 mM MgCl 2 . The samples were equilibrated at 25 °C for 30 min and then heated at a rate of 1 °C min -1 , while continuously monitoring the absorbance at 260 nm.
The Spectra Manager software (Jasco) was used to analyze the data and to calculate the DNA melting temperature (Tm).
Restriction enzyme cleavage assays
The effects of the different mithramycin analogues on the first-order rate constant at the individual restriction enzyme sites were determined as described elsewhere [15] . In brief, plasmid pBR322 was linearized by cleavage with BamHI (Fermentas). Bsp68I (NruI) and Eco52I (EagI) from Fermentas were used for restriction enzyme assays using the buffers supplied by the vendor. 
Cellular accumulation of mithramycin analogues
Ovarian cancer cells (1x10 4 cells) were incubated in RPMI 1640 medium with either DMSO or 100 mM of each mithramycin analogue. After 2 and 4 hours incubation, cells were repeatedly washed with ice-cold phosphate-buffered saline (PBS), harvested and immediately analyzed using a BD FACSCanto flow cytometer. Isolation of intact nuclei was carried out as described elsewhere [17] . Nuclei yield and integrity were confirmed by Trypan blue staining and microscopic examination. hours after DNA transfections. Luciferase activity was assayed using the Dual Luciferase
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Reporter System (Promega) and a Turner BioSystems TD20/20 luminometer.
Quantitative real-time RT-PCR assays
Total RNA was isolated from control cells (those to which no drug was added) and from Table 1 . PCR conditions included an initial denaturation step at 95 °C for 3 min, followed by 40 cycles at 95 °C for 20 s and an annealing step at 60 °C for 30 s, and an elongation step at 72 °C for 30 s. A final dissociation curve was generated to verify that a single product was amplified. Reactions in the absence of template and in the absence of enzyme were also included as negative controls. Relative expression values of the different genes were calculated from the threshold cycle (C t ) following the ∆∆C t method using GAPDH as an internal housekeeping control for gene expression normalization.
Statistical analysis
Statistical analysis was performed using SPSS v.20 (IBM Corp.) software. Results represent the mean ± SD, or mean ± SEM, values of three to six experiments. Two sample group differences were evaluated using the Student's t-test. Depending on the data characteristics and the number of independent experiments performed, multiple group comparison were assessed by either Kruskal-Wallis one-way analysis of variance and further pairwise Mann-Whitney U test analysis, or by one-way ANOVA with Tukey's post hoc test.
Results
The binding of DIG-MSK to DNA shows some differences compared to that of other mithramycins
As a first approach, we explored the binding of MTA, MSK and DIG-MSK to DNA by monitoring changes in DNA melting temperature (Tm) calculated from absorbance (at 260 nm)
versus temperature melting curves in the presence of mithramycin analogues ( Fluorescence titration experiments showed that DIG-MSK solutions titrated with increased concentration of calf thymus DNA behaved rather different in experiments performed at 25 ºC ( Fig. 2A ) and at 37 ºC (Fig. 2B ). While at 25 ºC fluorescence increased after adding higher concentrations of DNA, the same kind of experiments carried at 37 ºC showed that fluorescence was quenched. Moreover, after that an ∼5-6 DNA (bp)/drug molar ratio was reached there was no significant increase/decrease in fluorescence at either temperature, and therefore it was not possible to obtain experimental values that could be used to fit accurately binding models that require the emission intensity to be linearly proportional to the concentration of the drug [16] .
These results did not depend on the MgCl 2 concentration used (see Section 2). We have previously described the thermodynamic parameters of MSK binding to DNA based on similar fluorescence titrations, which rendered and apparent binding constant of 1.2 x 10 4 M -1 in a buffer containing 1.5 mM MgCl 2 [16] . In any case, from a mere qualitative point of view the superior protection of DNA melting by MSK ( Table 2 ) would indicate that MSK binds DNA tighter than DIG-MSK.
As a quantification of DIG-MSK binding was not attained, we followed a different approach to explore whether the difference between MSK and DIG-MSK sugar moieties ( Fig. 1 ) may result in differences in the DNA sequence that is preferentially recognized by the two analogues.
To this end, we analyzed the differential inhibition of restriction enzyme cleavage by MTA, MSK and DIG-MSK on a linearized DNA plasmid (Fig. 3) . MTA protected better than MSK or DIG-MSK both 5'-TCGCGA-3' (Bsp68I) and 5'-CGGCCG-3' (Eco52I) sequences from digestion ( Fig. 3) . Moreover, MSK was superior to DIG-MSK in abrogating Eco52I cleavage (p < 0.05; Fig. 3B ). Roughly speaking, the higher Tm values in the presence of MSK (Table 2) as well as the superior protection of 5'-CGGCCG-3' tracts by MSK (Fig. 3) were consistent with that MSK binds to DNA tighter than DIG-MSK, and that MSK can be more prone to accept different C/G-rich sequence arrangements at the binding site. The differences observed between the binding of MSK and DIG-MSK were a consequence of the distinct sugar E in the trisaccharide chain (Fig. 1) , which can entail changes in the interaction with DNA.
DIG-MSK accumulated in human ovarian tumor cell lines
Given that previous studies had revealed that mithramycins are highly active in gynecological cancer [17, 18] , we sought to unveil whether the cellular and nuclear accumulation of MTA, MSK and DIG-MSK in three human ovarian carcinoma cell lines was equivalent. Figure 4 shows that every mithramycin analogue fairly accumulated after 2h, while larger 4-h incubations did not result in a significant increase in drug accumulation. The three compounds also reached the nuclei of all the cell lines within 2 h. A comparison of the uptake of MTA or MSK between 2-h and 4-h treatments showed a time-dependent nuclear accumulation in IGROV1 and OVCAR3 cells (see legend to Fig. 4) . DIG-MSK accumulated in OVCAR3 nuclei with significant differences between 2-h and 4-h treatments, yet the drug levels were lower than of MTA (Fig. 4) . These experiments on cellular and nuclear accumulation indicated that the behavior of the mithramycins depended on the ovarian cell line used and the incubation time.
DIG-MSK is a potent inhibitor of Sp1-driven transcription and Sp1 expression
Because several mithramycins have been characterized as potent inhibitors of Sp1-activated transcription, we examined the effects of DIG-MSK on the expression of a transfected luciferase reporter vector containing several Sp1 response elements (CG-boxes). Since MTA is routinely used as a tool to assess whether Sp1 transactivates a variety of promoters in vivo (cell culture),
we employed it as a control to be compared to the new DIG-MSK in experiments undertaken in ovarian cancer cell lines. DIG-MSK retains the capacity of MTA to potently inhibit Sp1-driven promoter activity in A2780 and OVCAR3 cells, and it significantly inhibits (p < 0.01) the transcriptional activity in IGROV1 cells (Fig. 5A) . To strength the evidence, the effect of mithramycins on the Sp1-mediated promoter activity was also analyzed in cells treated with trichostatin A (TSA), an inhibitor of histone deacetylases that enhances Sp1-activation levels [30] . Figure 5B shows that even in the presence of TSA, MTA and DIG-MSK markedly reduced luciferase levels.
To characterize how the alteration of Sp1 levels impinge on the effect of DIG-MSK against the expression of Sp1-driven report plasmids, the Sp1-mediated promoter activity was enhanced by the transient co-transfection of an Sp1 expression vector in the different ovarian cell lines.
Sp1 over-expression enhanced about 15-fold the expression of the reporter plasmid in IGROV1 cells and about 3-fold in A2780 and OVCAR3 cells. In the presence of Sp1 expression vector, DIG-MSK showed an "anti-transcriptional effect" similar to that of the parental MTA in A2780
and OVCAR3 cells, whereas the relative inhibition was clearly higher in IGROV1 cells when compared to untreated cells (Fig. 5C ).
Given that the Sp1 gene is regulated by itself in a feedback positive manner, we next assessed the effects on the transcription of endogenous gene by treating ovarian cells with MTA and DIG-MSK, and the expression of the endogenous Sp1 was measured by qRT-PCR. DIG-MSK produced a significant inhibition (p < 0.01) of the expression of Sp1 in both A2780 and IGROV1 cells, which, nevertheless, was similar to that of MTA (Fig. 5D ). Taken together, these experiments indicate that DIG-MSK is a potent inhibitor of Sp1-mediated transcription and Sp1 gene expression in ovarian cells, a property it shares with the other mithramycin analogues.
DIG-MSK is stronger than MTA as inhibitor of Sp3 expression and Sp3-mediated transcription
Sp3 is a member of the family of Sp1-related genes that also binds to C/G-rich boxes. We examined the capacity of DIG-MSK for inhibiting Sp3-driven transcription. As a first approach, a luciferase reporter plasmid under the control of the ULBP1 promoter was used since Sp3 is a potent and specific regulator of ULBP1 transcription, which is able to induce more than 500-fold the promoter activity of the gene [26] . MTA and DIG-MSK inhibited ULBP1 promoter activity in A2780 and IGROV1, while the inhibitory capacity of DIG-MSK was higher than of MTA in IGROV1 cells (Fig. 6A) . Sp1 stimulates the activity of a variety of promoters, while Sp3 is a bifunctional transcription factor that either stimulates or represses the transcription of ULBP1, among other genes. Interestingly, the luciferase activity driven by the ULBP1 promoter activity was up-regulated in OVCAR3 cells by MTA and DIG-MSK (Fig. 6A) . Seemingly, in this cell line Sp3 could gain access to the promoter acting as activator in the presence of the compounds, yet the three ovarian cell lines can differ in the abundance and activity of the Sp3 isoforms. To further characterize the effect of DIG-MSK on Sp3-mediated promoter activity, Sp3 was overexpressed in the ovarian cell lines by transient transfection of an Sp3-expression vector and the promoter activity was analyzed by using a luciferase reporter vector that contains several C/Grich response elements. DIG-MSK was stronger than MTA in inhibiting the promoter activity induced by Sp3 over-expression in the three ovarian cell lines (Fig. 6B ).
The effect of MTA and DIG-MSK on the expression of the endogenous Sp3 and UBLP1 vitro EMSA (electrophoretic mobility assays) that showed that DIG-MSK displaces Sp1 from its putative binding sites [20] .
The novel mithramycin analogue DIG-MSK down-regulated the expression of a variety of endogenous genes in human ovarian cancer cells
To further assess the relevance of the effects of DIG-MSK on gene expression, we studied a (Fig. 7A) . However, DIG-MSK was not efficient in abrogating the expression of E2F1 in A2780 cells (Fig. 7A) , whereas it was rather active on the same gene in the other ovarian cancer cells (Figs. 7B and 7C) . Besides, the three compounds did not downregulate the endogenous Sp1 gene in OVCAR3 cells (Fig. 7C) . In IGROV1 and OVCAR3 cells
Sp3 expression was strongly reduced, with a superior effect of DIG-MSK (Figs. 7B and 7C ).
DIG-MSK was a strong inhibitor of both Sp3 and the ULBP1 gene expression, the latter being strongly Sp3-dependent, as described above.
Discussion
MSK has an improved therapeutic index compared to the parental MTA [4, 17] and it inhibits the transcription of several genes [17, 31] , which is likely to occur, at least in part, by direct abrogation of the Sp1-transactivating effects on gene expression [14, 32] . Here, we show that the novel analogue DIG-MSK also binds to DNA and it alters gene expression, which may be a desirable mechanism of intervention in certain cancers [33] . Furthermore, DIG-MSK entails an improved pharmacological profile with high antitumor activity and less toxicity [13] .
In a previous paper, we calculated by fluorescence titration the binding of several mithramycin analogues to DNA [16] . However, when we used the same approach to analyze the DNA binding of the new DIG-MSK we did not obtain a reliable apparent binding constant (K obs ), see Section 3. DIG-MSK shows a rather peculiar behavior because its fluorescence was enhanced or quenched by DNA depending on the temperature. We are at a loss to explain why such fluorescence behavior ensued, although examples exist of DNA-binding agents which fluorescence can be enhanced or quenched upon binding [34] . In our experiments it is peculiar that this phenomenon is observed with the same molecule binding to DNA at different temperatures. From a qualitative point of view, we can infer that the binding of DIG-MSK to DNA is similar to that of other MTA analogues, thus producing changes in gene expression.
We used a promoter-luciferase reporter driven by Sp1-responsive elements to characterize whether DIG-MSK interferes with basal and induced Sp1-driven transcription (Fig. 5) . The effects of DIG-MSK on gene expression are higher than of MTA in some ovarian cell lines (Figs. 5-7 ). Sp1 is a well-known member of a growing family of transcription factors that also includes Sp3, which display similar DNA binding characteristics, but also some different functional properties [22, 25, 35] . Together with the effect of mithramycins on Sp1, we have also analyzed the effects on Sp3-mediated transcription and Sp3 gene expression. To differentiate the specific effects of Sp3 from Sp1 ones, we assessed the effects of DIG-MSK on the ULBP1 promoter activity. ULBP1, a predictor of poor prognosis in ovarian cancer patients [28] , is one of the few genes in which Sp3, but not Sp1, has been reported to be a specific and strong regulator of its transcription [26] . The effect on Sp3-mediated transcription was further analyzed by overexpressing Sp3 in the ovarian cell lines. In general, DIG-MSK is equivalent or significantly stronger than the parental MTA in inhibiting Sp3-mediated transcription. DIG-MSK has a superior inhibiting effect on the expression of endogenous Sp3 and ULBP1 genes (Figs. 6 and 7) .
Because of the ubiquitous expression of Sp3, and its role in regulating a wide variety of genes,
we suggest that such differences may contribute to the distinct pharmacological profile of DIG-MSK. In OVCAR3 cells, the three mithramycins had little effect on Sp1 gene expression, regardless of their effects on other endogenous Sp1-responsive genes (Fig. 7C ). This peculiarity may arise from the large polymorphism observed in the Sp1/Sp3 binding-sites in OVCAR cells, which could protect them against time-dependent silencing [36] .
Given that Sp1 is an important regulator of the expression of multiple angiogenic factors [22] , the down-regulation of VEGF-C by the new MSK and DIG-MSK (Fig. 7) might have clinical implications, as it has been suggested for the parental MTA [9] . DIG-MSK would be advantageous on account of its lower toxicity. The superior effect of DIG-MSK on the expression of CCNB1 (cyclin B1) in A2780 cells (Fig. 7A) is consistent with the effects of this compound on genes involved in cell cycle control in colon carcinoma cells [20] . In transfected IGROV1 cells the down-regulation of Sp1-driven luciferase expression, as well as the down-regulation of a set of cellular genes which includes Sp1, Sp3 and ULBP1, by DIG-MSK correlates with its superior antitumor effect on these cells [13] .
All the mithramycin analogues bind to DNA significantly and they interfere with the transcription machinery. Nevertheless, the improved characteristics of MSK and DIG-MSK can be a consequence of other aspects like their selective accumulation in certain cells and tissues, (Fig. 4 and [13, 15, 17] ). In fact, the lower systemic toxicity of DIG-MSK suggests a selective distribution of this analogue [13] , in keeping with our results. Altogether, the novel DIG-MSK is interesting in the pursuit of improved targeting in the treatment of ovarian cancer [37] .
In summary, the distinctive antitumor activities of MSK and DIG-MSK against several experimental models and the different cytotoxic effects might be attributed to the differential capacity of these molecules for traversing cell membranes, which can result in direct binding to 
